1-Ethyl-3-(3'-dimethylaminopropyl)carbodiimide → HCID 59559573、化合物
反応式
CCN(C(C)C)C(C)C.[N:10]1[CH:15]=[CH:14][N:13]=[CH:12][C:11]=1[C:16]1[CH:24]=[CH:23][C:19]([C:20]([OH:22])=O)=[CH:18][CH:17]=1.C1C=CC2N(O)N=NC=2C=1.CCN=C=NCCCN(C)C.Cl.[NH2:47][CH2:48][C:49]([N:51]1[CH2:56][CH2:55][N:54]([C:57](=[O:68])[C:58]2[CH:63]=[CH:62][CH:61]=[CH:60][C:59]=2[C:64]([F:67])([F:66])[F:65])[CH2:53][CH2:52]1)=[O:50]>CN(C=O)C.C(OCC)(=O)C.O>[O:50]=[C:49]([N:51]1[CH2:52][CH2:53][N:54]([C:57](=[O:68])[C:58]2[CH:63]=[CH:62][CH:61]=[CH:60][C:59]=2[C:64]([F:67])([F:66])[F:65])[CH2:55][CH2:56]1)[CH2:48][NH:47][C:20](=[O:22])[C:19]1[CH:18]=[CH:17][C:16]([C:11]2[CH:12]=[N:13][CH:14]=[CH:15][N:10]=2)=[CH:24][CH:23]=1参加物
反応物 5
生成物 1
試薬・触媒・溶媒 3
実験手順
DIPEA (96 mg, 0.12 mL, 0.74 mmol) was added to a stirred solution of 4-pyrazin-2-yl-benzoic acid (50 mg, 0.24 mmol) in DMF (2 mL). HOBT (40 mg, 0.23 mmol) and EDCI (57 mg, 0.29 mmol) were then added at room temperature. After 2 minutes 2-amino-1-[4-(2-trifluoromethyl-benzoyl)-piperazin-1-yl]-ethanone hydrochloride salt (105 mg, 0.29 mmol) was added and the resulting mixture was stirred at room temperature overnight. Cold water was then added and then extrated with ethyl acetate. The organic layer was washed with brine and dried over Na2SO4 and concentrated under reduced pressure to afford 78 mg (63.4%) of N-{2-oxo-2-[4-(2-trifluoromethyl-benzoyl)-piperazin-1-yl]-ethyl}-4-pyrazin-2-yl-benzamide. LCMS Purity: 96.69%. 1H NMR (DMSO-d6): δ 9.4-9.3 (d, 1H), 8.8-8.7 (m, 2H), 8.7-8.6 (d, 1H), 8.3-8.2 (d, 1H), 8.1-8.0 (d, 2H), 7.9-7.6 (m, 3H), 7.6-7.5 (bt, 1H), 4.3-4.1 (m, 2H), 3.8-3.54 (m, 4H), 3.54-3.4 (m, 2H), 3.2-3.04 (m, 2H).
後処理
- washThe organic layer was washed with brine
- dry with materialdried over Na2SO4
- concentrationconcentrated under reduced pressure
出典と根拠
- ORDレコード
- ord-682d5db140a54a05aa7f45d37e4ce4a1
- 出典データセット
- uspto-grants-2010_11
- 特許番号
- US07842696B2
反応ノート
読み込み中…